KR20230080442A - 폐암의 검출 및 치료를 위한 방법 - Google Patents

폐암의 검출 및 치료를 위한 방법 Download PDF

Info

Publication number
KR20230080442A
KR20230080442A KR1020237014384A KR20237014384A KR20230080442A KR 20230080442 A KR20230080442 A KR 20230080442A KR 1020237014384 A KR1020237014384 A KR 1020237014384A KR 20237014384 A KR20237014384 A KR 20237014384A KR 20230080442 A KR20230080442 A KR 20230080442A
Authority
KR
South Korea
Prior art keywords
biological sample
subject
sftpb
pro
cea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014384A
Other languages
English (en)
Korean (ko)
Inventor
사미르 한나쉬
에드윈 오스트린
지딩 펑
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20230080442A publication Critical patent/KR20230080442A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G01N33/57423—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020237014384A 2020-10-02 2021-09-29 폐암의 검출 및 치료를 위한 방법 Pending KR20230080442A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063086865P 2020-10-02 2020-10-02
US63/086,865 2020-10-02
US202063106187P 2020-10-27 2020-10-27
US63/106,187 2020-10-27
PCT/US2021/052611 WO2022072471A1 (en) 2020-10-02 2021-09-29 Methods for the detection and treatment of lung cancer

Publications (1)

Publication Number Publication Date
KR20230080442A true KR20230080442A (ko) 2023-06-07

Family

ID=80950972

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014384A Pending KR20230080442A (ko) 2020-10-02 2021-09-29 폐암의 검출 및 치료를 위한 방법

Country Status (6)

Country Link
US (1) US20240159753A1 (https=)
EP (1) EP4222287A4 (https=)
JP (1) JP2023545017A (https=)
KR (1) KR20230080442A (https=)
CA (1) CA3163498A1 (https=)
WO (1) WO2022072471A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7311417B2 (ja) * 2017-02-09 2023-07-19 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 肺癌の検出および処置のための方法
AU2021213150A1 (en) 2020-01-30 2022-08-04 Prognomiq Inc Lung biomarkers and methods of use thereof
WO2022212583A1 (en) 2021-03-31 2022-10-06 PrognomIQ, Inc. Multi-omic assessment
GB2607436A (en) * 2021-03-31 2022-12-07 Prognomiq Inc Multi-omic assessment
WO2023039479A1 (en) 2021-09-10 2023-03-16 PrognomIQ, Inc. Direct classification of raw biomolecule measurement data
CN118215845A (zh) 2021-09-13 2024-06-18 普罗科技有限公司 增强的对生物分子的检测和定量
WO2024107923A1 (en) * 2022-11-17 2024-05-23 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer
WO2024249401A2 (en) * 2023-05-31 2024-12-05 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer
GB202310137D0 (en) * 2023-07-03 2023-08-16 Belgian Volition Srl Method for the detection of cancer
WO2025064345A2 (en) * 2023-09-22 2025-03-27 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610127B1 (en) * 2003-03-11 2012-04-25 CRC Inc. N1,n12-diacetylspermine as tumor marker
ES2553442T3 (es) * 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
SG186953A1 (en) * 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
WO2013154998A1 (en) * 2012-04-09 2013-10-17 Duke University Serum biomarkers and pulmonary nodule size for the early detection of lung cancer
US9753037B2 (en) * 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
US11656229B2 (en) * 2015-06-26 2023-05-23 Biomark Cancer Systems Inc. Method of detecting lung cancer
CN118522390A (zh) * 2016-04-01 2024-08-20 20/20基因系统股份有限公司 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物
EP3361256A1 (en) * 2017-02-08 2018-08-15 Fundación para la Investigación Médica Aplicada In vitro method for the diagnosis of lung cancer
JP7311417B2 (ja) * 2017-02-09 2023-07-19 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 肺癌の検出および処置のための方法

Also Published As

Publication number Publication date
WO2022072471A1 (en) 2022-04-07
EP4222287A4 (en) 2024-12-18
CA3163498A1 (en) 2022-04-07
JP2023545017A (ja) 2023-10-26
EP4222287A1 (en) 2023-08-09
US20240159753A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
US20240159753A1 (en) Methods for the detection and treatment of lung cancer
US20230393150A1 (en) Methods and algorithms for aiding in the detection of cancer
US12405274B2 (en) Methods for the detection and treatment of lung cancer
US11193935B2 (en) Compositions, methods and kits for diagnosis of lung cancer
Roe et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study
US20180100858A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
Marmor et al. Biomarkers in lung cancer screening: a narrative review
Li et al. Five tumor-associated autoantibodies expression levels in serum predict lung cancer and associate with poor outcome
WO2024107923A1 (en) Methods for the detection and treatment of lung cancer
CN108369233B (zh) 基于标志物人附睾蛋白4 (he4)检测肺腺癌的复发的方法及相关用途
WO2015042454A1 (en) Compositions, methods and kits for diagnosis of lung cancer
WO2022140576A1 (en) Blood-based protein biomarker panel for early and accurate detection of cancer
CN116529603A (zh) 用于检测和治疗肺癌的方法
HK40105704A (zh) 肺癌的检测和治疗方法
Kumari et al. Exploring Biomarker-Based Multivariate Index Algorithm as a Tool in Detecting Risk of Cancer in Ovarian Mass
Xie et al. An ABCC1-based risk model is effective in the diagnosis of synchronous peritoneal metastasis in advanced colorectal cancer: Molecular Diagnostics

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000